Nkarta, Inc. (NKTX) NASDAQ
2.98
-0.11(-3.56%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.98
-0.11(-3.56%)
Currency In USD
| Previous Close | 3.09 |
| Open | 3.07 |
| Day High | 3.09 |
| Day Low | 2.85 |
| 52-Week High | 3.65 |
| 52-Week Low | 1.63 |
| Volume | 1.05M |
| Average Volume | 779,560 |
| Market Cap | 212.45M |
| PE | -2.11 |
| EPS | -1.41 |
| Moving Average 50 Days | 2.39 |
| Moving Average 200 Days | 2.14 |
| Change | -0.11 |
Nkarta to Participate in Evercore Healthcare Conference
GlobeNewswire Inc.
Dec 02, 2025 12:09 PM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its partic
Nkarta to Participate in November Investor Conferences
GlobeNewswire Inc.
Oct 30, 2025 5:14 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following inve
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
GlobeNewswire Inc.
Oct 22, 2025 2:07 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be